KODIAK SCIENCES INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.28 USD | +2.98% |
|
-2.38% | +7.89% |
| Apr. 04 | UBS Adjusts Kodiak Sciences Price Target to $5 From $3, Maintains Neutral Rating | MT |
| Apr. 01 | Barclays Raises Price Target on Kodiak Sciences to $3 From $2, Maintains Underweight Rating | MT |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 172M |
|---|---|---|---|---|---|
| Net income 2024 * | -225M | Net income 2025 * | -267M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 58.45M | Net cash position 2025 * | 8.2M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-0.8
x | P/E ratio 2025 * |
-0.86
x | Employees | 111 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.34% |
More Fundamentals
* Assessed data
More news
Latest transcript on Kodiak Sciences Inc.
More recommendations
More press releases
| 1 day | +2.98% | ||
| 1 week | -2.38% | ||
| Current month | -37.64% | ||
| 1 month | -53.80% | ||
| 3 months | -34.14% | ||
| 6 months | +126.21% | ||
| Current year | +7.89% |
1 week
3.17
3.56
1 month
3.176.88
Current year
2.877.77
1 year
1.379.80
3 years
1.37131.97
5 years
1.37171.21
10 years
1.37171.21
| Managers | Title | Age | Since |
|---|---|---|---|
Victor Perlroth
CEO | Chief Executive Officer | 51 | 08-12-31 |
John Borgeson
DFI | Director of Finance/CFO | 62 | 15-12-31 |
| Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Felix Baker
BRD | Director/Board Member | 55 | 15-08-31 |
Tai Yin Yang
BRD | Director/Board Member | 70 | 19-12-16 |
Richard Levy
BRD | Director/Board Member | 66 | 18-07-17 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 0 M€ | 0.00% | - | |
| 0.03% | 0 M€ | 0.00% | - | |
| 0.00% | 9 M€ | +6.26% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 3.28 | +2.98% | 252,121 |
| 24-04-25 | 3.185 | -5.77% | 322,041 |
| 24-04-24 | 3.38 | +1.50% | 455,004 |
| 24-04-23 | 3.33 | -2.63% | 327,654 |
| 24-04-22 | 3.42 | +1.79% | 314,299 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotes
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
3.28
USD
Average target price
4.25
USD
Spread / Average Target
+29.57%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +7.89% | 167M | |
| -2.31% | 103B | |
| +0.56% | 95.71B | |
| +1.69% | 22.02B | |
| -17.37% | 20.9B | |
| -9.30% | 17.85B | |
| -41.01% | 16.21B | |
| -14.85% | 15.52B | |
| +3.21% | 13.86B | |
| +33.54% | 12.04B |
- Stock Market
- Equities
- KOD Stock
